Background: We performed a multicenter retrospective observational study to investigate the impact of clinical-pathological features and therapeutic strategies on both the complications and survival of patients with bone metastases (BMs) from malignant melanoma.
Patients And Methods: A total of 305 patients with melanoma and radiological evidence of BMs were retrospectively enrolled from 19 Italian centers. All patients received conventional treatments in accordance with each own treating physician's practice. Both univariate and multivariate models were used to explore the impact of melanoma features, including skeletal-related events (SREs), and different treatments on both overall survival (OS) and time-to-SREs. The chi-squared test evaluated the suitability of several parameters to predict the occurrence of SREs.
Results: Eighty-three percent of patients had metachronous BMs. The prevalent (90%) bone metastatic site was the spine, while 45% had involvement of the appendicular skeleton. Forty-seven percent experienced at least one SRE, including palliative radiotherapy (RT) in 37% of cases. No melanoma-associated factor was predictive of the development of SREs, although patients receiving early treatment with bone-targeted agents showed 62% lower risk and delayed time of SRE occurrence. Median OS from the diagnosis of bone metastasis was 10.7 months. The multivariate analysis revealed as independent prognostic factors the number of BMs, number of metastatic organs, baseline lactate dehydrogenase levels, and treatment with targeted therapy or immunotherapy. Subgroup analyses showed the best OS (median = 16.5 months) in the subset of patients receiving both immunotherapy and palliative RT.
Conclusion: Based on our results, patients undergoing immunotherapy and palliative RT showed an OS benefit suggestive of a possible additive effect. The apparent protective role of bone targeting agent use on SREs observed in our analysis should deserve prospective evaluation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523509 | PMC |
http://dx.doi.org/10.3389/fonc.2020.01652 | DOI Listing |
J Clin Med
December 2024
Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, Turkey.
: Although CDK4/6 inhibitors combined with endocrine therapies have improved outcomes in HR+ HER2-negative metastatic breast cancer, predictive biomarkers for treatment response and adverse effects remain limited. This study assessed the prognostic and predictive value of large unstained cells (LUC), a subset of white blood cells that may reflect immune status or treatment response. : A retrospective analysis of 210 patients with HR+ HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors between 2021 and 2024 was conducted.
View Article and Find Full Text PDFDiagnostics (Basel)
December 2024
Orthopedic Surgery, Macquarie University Hospital, Sydney, NSW 2113, Australia.
: Giant cell tumor of bone (GCTB) is a locally aggressive tumor. It accounts for only 5% of all bony tumors. Early diagnosis, and follow-up for recurrence is often difficult due to a lack of biogenetic markers.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla 1, 50134 Florence, Italy. Electronic address:
Introduction: Distant recurrences are a major problem after surgical treatment for endometrial carcinoma; metastases to the bone are usually restricted to the axial skeleton, cases of costal localization are few. We present a case of a massive costal metastases successfully treated in our department.
Case Presentation: A 60-year-old woman underwent bilateral hysteroannessectomy followed by adjuvant radiotherapy for endometrial adenocarcinoma pT3a FIGO IIIA.
Medicine (Baltimore)
January 2025
Department of Bone and Joint Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Rationale: Synovial sarcoma (SS) is a rare and highly malignant soft tissue sarcoma. When SS occurs in atypical locations, it can present significant diagnostic challenges. We report a case of paraspinal SS initially misdiagnosed as spinal tuberculosis, highlighting the diagnostic difficulties and the importance of considering SS in the differential diagnosis.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
Department of Oncology, University of Torino, Via Nizza 44, 10126, Turin, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!